Sep 14, 2021 / 04:30PM GMT
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity Analyst
Hi, everyone. Thanks for joining us at the Morgan Stanley Healthcare Conference. I'm Tejas Savant, and I cover the life science tools and diagnostics sector here at Morgan Stanley.
Delighted to have Invitae join us this morning. And representing the company is Sean George, CEO; and Roxi Wen, CFO. So welcome to you both.
Before we get into the Q&A, I just have a quick safe harbor to rattle off. For important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your sales rep.
So with that, Sean, thanks for joining us. Maybe just to set the stage, can you walk us through Invitae's portfolio transformation? I think at last count, you guys have done something like 17 acquisitions over the last few years as you sort of progress towards the development of a digitally enabled genome management business model.
And on a related note, have you started to think of bundling some of those
Invitae Corp at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Feb 14, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers